“Magic Bullets” at the center stage of immune therapy: a special issue on therapeutic antibodies
Published date: 01 Mar 2018
Copyright
Zhiqiang An . “Magic Bullets” at the center stage of immune therapy: a special issue on therapeutic antibodies[J]. Protein & Cell, 2018 , 9(1) : 1 -2 . DOI: 10.1007/s13238-017-0488-1
1 |
An Z (2009) Therapeutic monoclonal antibodies: from bench to clinic. Hoboken, Wiley
|
2 |
An Z (2010) Monoclonal antibodies—a proven and rapidly expanding therapeutic modality for human diseases. Protein Cell 1:319–330
|
3 |
Bardwell PD, Staron MM, Liu J, Tao Q, Scesney S, Bukofzer G, Rodriguez LE, Choi CH, Wang J, Chang Q,
|
4 |
Emmons C, Hunsicker LG (1987) Muromonab-CD3 (Orthoclone OKT3): the first monoclonal antibody approved for therapeutic use. Iowa Med 77:78–82
|
5 |
Kang C, Xia L, Chen Y, Zhang T, Wang Y, Zhou B, You M, Yuan Q, Tzeng CM, An Z,
|
6 |
Kohler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495–497
|
7 |
Liu L (2017) Pharmacokinetics of monoclonal antibodies and Fcfusion proteins. Protein Cell 9:15–32
|
8 |
Mimura Y, Katoh T, Saldova R, O’Flaherty R, Izumi T, Mimura-Kimura Y, Utsunomiya T, Mizukami Y, Yamamoto K, Matsumoto T,
|
9 |
Simeon R, Chen Z (2017) In vitro-engineered non-antibody protein therapeutics. Protein Cell 9:3–14
|
10 |
Strohl WR (2017) Current progress in innovative engineered antibodies. Protein Cell 9:86–120
|
11 |
Tan S, Liu K, Chai Y, Zhang CW, Gao S, Gao GF, Qi J (2017) Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab. Protein Cell 9:135–139
|
12 |
Tsuchikama K, An Z (2016) Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell 9:33–46
|
13 |
Wang X, An Z, Luo W, Xia N, Zhao Q (2017a) Molecular and functional analysis of monoclonal antibodies in support of biologics development. Protein Cell 9:74–85
|
14 |
Wang X, Mathieu M, Brezski RJ (2017b) IgG Fc engineering to modulate antibody effector functions. Protein Cell 9:63–73
|
/
〈 | 〉 |